Pamidronate
FDA Approved
Description
Pamidronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption and is used to treat various bone disorders. It has been used off-label in polyostotic fibrous dysplasia to reduce bone pain and fracture risk. Clinical studies have shown improvement in bone density and reduction in skeletal complications.
Indications & Therapeutic Use
Paget's disease of bone, hypercalcemia of malignancy, osteolytic bone metastases, polyostotic fibrous dysplasia (off-label)
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Pamidronate
| Generic Name | Pamidronate |
| Brands | 1 brand available |
| Active Ingredient | Pamidronate disodium |
| Drug Class | Paget's disease of bone |
| Manufacturer | Novartis |
| Dosage Forms | IV infusion, 30mg, 60mg, 90mg powder for reconstitution |
| Medical Code | M05BA03 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00001727 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes